Evidence map›Paper›PMID 21147894›Full record

ArticleNicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco2011

Adherence to and reasons for premature discontinuation from stop-smoking medications: data from the ITC Four-Country Survey.

James Balmford, Ron Borland, David Hammond, K Michael Cummings

Abstract read
In one paragraph

Article in Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 82 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
82citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

82 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. An Automated, Online Feasibility Randomized Controlled Trial of a Just-In-Time Adaptive Intervention for Smoking Cessation (Quit Sense).Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco · 2023
    Trial
  6. Trial
  7. Trial
  8. Electronically Monitored Nicotine Gum Use Before and After Smoking Lapses: Relationship With Lapse and Relapse.Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco · 2020
    Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Predictors of Varenicline Adherence Among Cancer Patients Treated for Tobacco Dependence and its Association With Smoking Cessation.Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco · 2019
    Trial
  14. Trial
  15. Trial
  16. Trial
  17. Trial
  18. Trial
  19. Trial
  20. Trial

22 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

James BalmfordVicHealth Centre for Tobacco Control, The Cancer Council Victoria, 1 Rathdowne St Carlton VIC 3053, Melbourne, Australia. james.balmford@cancervic.org.au
Ron Borland
David Hammond
K Michael Cummings

Funding

Two-Spirit Films in Indigenous Cancer HealthP30CA016056 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · PI CANDACE S JOHNSON · 1985 to 2026
$116.6M
Variation in Cigarettes, Tobacco use Behaviors and Exposures in ITC CountriesP01CA138389 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · PI FONG, GEOFFREY T · 2009 to 2013
$13.4M
Project 3: Policy Effects on Cigarette Design, Emissions &BehaviorP50CA111236 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · PI CUMMINGS, KENNETH MICHAEL · 2004 to 2009
$8.2M
International Tobacco Policy SurveyR01CA100362 · NCI · UNIVERSITY OF WATERLOO · PI FONG, GEOFFREY T · 2005 to 2013
$4.7M
Cancer Research UK C312/A6465CIHR 79551NCI NIH HHS P01 CA138389NCI NIH HHS P30 CA016056NCI NIH HHS P50 CA111236NCI NIH HHS R01 CA100362
6 · The paper itself

Abstract

introductionNicotine replacement therapies (NRTs) have been demonstrated to be effective in clinical trials but may have lower efficacy when purchased over-the-counter (OTC). Premature discontinuation and insufficient dosing have been offered as possible explanations. The aims are to (a) investigate the prevalence of and reasons for premature discontinuation of stop-smoking medications (including prescription only) and (b) how these differ by type, duration of use, and source (prescription or OTC).

methodsThe sample includes 1,219 smokers or recent quitters who had used medication in the last year (80.5% NRT, 19.5% prescription only). Data were from Waves 5 and 6 of the International Tobacco Control (ITC) Four-Country Survey.

resultsMost of the sample (69.1%) discontinued medication use prematurely. This was more common among NRT users (71.4%) than in users of bupropion and varenicline (59.6%). OTC NRT users were particularly likely to discontinue (76.3%). Relapse back to smoking was the most common reason for discontinuation of medication reported by 41.6% of respondents. Side effects (18.3%) and believing that the medication was no longer needed (17.1%) were also commonly reported. Of those who completed treatment, 37.9% achieved 6-month continuous abstinence compared with 15.6% who discontinued prematurely. Notably, 65.6% who discontinued because they believed the medication had worked were abstinent.

conclusionsPremature discontinuation of stop-smoking medications is common but is not a plausible reason for poorer quit outcomes for most people. Encouraging persistence of medication use after relapse or in the face of minor side effects may help increase long-term cessation outcomes.

Indexed as

AdolescentAdultAgedAustraliaBenzazepinesBupropionCanadaCohort StudiesData CollectionDrug MonitoringFemaleHumansMaleMedication AdherenceMiddle AgedNicotineBenzazepinesBupropionNicotineNonprescription DrugsPrescription DrugsQuinoxalinesVarenicline

Identifiers

PMID21147894
PMCPMC3028191

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.